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Abstract 
Review on Osteosarcoma, with data on clinics, and 





Osteosarcoma, not otherwise specified; 
Chondroblastic osteosarcoma; Fibroblastic 
osteosarcoma; Osteofibrosarcoma; Central 
osteosarcoma; Conventional central osteosarcoma; 
Medullary osteosarcoma; Intracortical 
osteosarcoma; Classical osteosarcoma;Osteogenic 
sarcoma; Osteoblastic sarcoma; Central osteogenic 
sarcoma; Conventional central osteosarcoma; 
Sclerosing osteosarcoma. 
Note 
Some of the above mentioned aliases are based on 
the anatomical location (Medullary osteosarcoma, 
Intracortical osteosarcoma), histological, with 
respect to the constitution of the extra cellular matrix 
(ECM) and/or radiological appearance 
(Chondroblastic osteosarcoma, Fibroblastic 
osteosarcoma, Osteoblastic sarcoma, Sclerosing 
osteosarcoma) of the tumor. Others are referring to 
the characteristic appearance of osteosarcoma 
without further specifying (conventional, central). 
Secondary osteosarcomas (mainly linked with 
Paget's disease of bone of post-radiation sarcomas) 
and extra medullary osteosarcomas (Parosteal 
osteosarcoma, Periosteal osteosarcoma) share many 
features with conventional osteosarcoma, but also 
have additional characteristics. Some of these 
subtypes of osteosarcoma are discussed in the 
chapter osteogenic tumors. 
Classification 
Note 
Conventional osteosarcomas are classified in terms 
of predominant ECM:  
Osteoblastic osteosarcoma:  predominantly 
bony/osteoid matrix  
Chondroblastic osteosarcoma:  predominantly 
chondroid matrix  
Fibroblastic osteosarcoma:  predominantly spindle 
cells, low osteoid  
Unusual histological forms with the same clinical 
behavior Intermediary forms may occur, consisting 
of mixed ECM types. 
Clinics and pathology 
Disease 
Conventional osteosarcoma is a high grade 
malignant primary central sarcoma of 
bonecharacterized by the presence of osteoid 
extracellular matrix. 
Etiology 
There are no benign precursors of osteosarcoma 
identified till now, however an association between 
Paget's disease of bone and post-radiation sarcoma 
with secondary osteosarcoma is suggested. Patients 
with genetic syndromes including Li-Fraumeni 
syndrome (TP53 mutation), hereditary 
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retinoblastoma (RB1 mutation), and Rothmund-
Thompson (RECQL4 mutation), have a higher 
chance of developing osteosarcoma. Benign bone-
forming neoplasms very rarely undergo malignant 
transformation. Currently there is no consensus on 
the progenitor cell of osteosarcoma. Mesenchymal 
stem cells (MSCs) potentially are the progenitor 
cells as these cells have the capability to differentiate 
towards the osteogenic lineage. In a model of murine 
MSCs that spontaneously transformed during ex 
vivo expansion, the transformed MSCs formed 
osteosarcoma in mice when these MSCs were 
injected. Although spontaneous malignant 
transformation is not described for human MSCs to 
this date, human MSCs transformed upon RB1 
knockdown and MYC overexpression. After 
injection into mice these transformed human MSCs 
also lead to osteosarcoma formation. However, a 
more differentiated precursor cell such as an 
osteoblast could also be the progenitor cell of 
osteosarcoma. Conditional deletion of RB1 and 
TP53 in differentiated bone marrow derived murine 
MSCs transformed these cells and formed 
osteosarcoma in mice. Undifferentiated murine 
MSCs with deletion of RB1 and TP53 formed 
leiomyosarcoma leiomyosarcoma and not 
osteosarcoma. As there is evidence that both 
osteoblast and undifferentiated MSCs can be the 
progenitor cells of osteosarcoma, it is also likely that 
both cell types are the precursor. 
Epidemiology 
Osteosarcoma is the most common primary 
malignant bone tumor of non-haematopoietic origin 
with an incidence of 4 per million people aged 
between 0-24 years or >60 years and 1.7 per million 
people in the age group 25-59.There is no 
association with ethnic group or race. The disease 
mostly affects children and young adults (70%), but 
a secondary smaller peak incidence (30%) is seen in 
patients over 40 years of age. However for these late 
onset osteosarcomas a predisposing condition, as 
Paget's disease or post-radiation sarcoma can often 
be causal. Males are more frequently affected than 
females in a ratio of 1.35:1, possibly because of the 
more irregular growth spurt in young males than in 
females. 
Clinics 
Symptoms, mainly deep pain, develop over a period 
of weeks to a few months until they become 
unbearable. This non-specific pain either combined 
with a palpable mass or not is the cardinal symptom 
of conventional osteosarcoma. Also edema and 
localized warmth may be included to the symptoms 
as is the limitation of the patient's motions. 
Pathological fractures occur in 5-10% of the patients.  
Macroscopy: Conventional osteosarcoma can arise 
in any bone, but most often affects the ends of the 
long bones, in particular the distal femur (30%), 
proximal tibia (15%) and proximal humerus (15%). 
It is often a fleshy or hard tumour 5-10 cm in size 
localized at the metaphysis (90%) or diaphysis 9%) 
and very rarely the epiphysis of the bone. 
Conventional osteosarcoma frequently penetrates 
the cortex and is associated with a soft tissue mass.  
Radiography: The overall radiographic appearance 
of conventional osteosarcoma is a mixed 
lytic/sclerotic lesion with cortical destruction and 
tumor expansion into soft tissue. Sometimes a so-
called Codman's triangle is observed when the tumor 
raises the periosteum away from the bone. To 
evaluate the extent of the tumor preoperative CT 
scan, and (dynamic) MRI may be helpful. 
Furthermore dynamic MRI is useful to monitor the 
effect of neoadjuvant chemotherapy. 
 
Figure 1. Radiographic picture of an osteosarcoma 
located at the proximal part of the tibia. The red circled area 
shows the characteristic osteogenic view with some 
osteolytic parts (green arrows). 
Cytology 
Cells are often highly anaplastic, and can be 
epitheloid, plasmacytoid, fusiform, ovoid orsmall 
and round cells. Giant cells can be seen.  
Microscopy: The main hematoxylin and eosin stain 
(HE) based characteristic of osteosarcoma is the 
identification of osteoid which is dense, pink, 
amorphous extra cellular material containing large 
amounts of collagen type I. Metastases are mostly 
similar in histology to the primary tumor with 
respect to growth rate and ECM, but exceptions 
occur. Histochemical staining of alkaline 
phosphatase can demonstrate the osteoblastic nature 
of the tumor. Novel immunohistochemical markers 
SATB2 and DMP1 demonstrate osteogenic 
differentiation, but these are not entirely specific for 
osteosarcoma. 
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Figure 2. Osteoblastic osteosarcoma 
 
Figure 3. Chondroblastic osteosarcoma 
 
Figure 4. Fibroblastic osteosarcoma 
 
Treatment 
Conventional osteosarcoma is considered to be a 
systemic disease and universally fatal if untreated. 
The current treatment is a combination of 
chemotherapy and surgery. Patients receive multi-
component neoadjuvant chemotherapy which 
facilitates limb-sparing surgery instead of 
amputation by decreasing tumor mass and 
suppressing micrometastases. Most often patients 
are also given chemotherapy after surgery at high 
doses to prevent metastatic spread. The most 
effective cytostatics in osteosarcoma are 
doxorubicin, cis-platinum and methotrexate. Drugs 
directed at receptor tyrosine kinases, such as drugs 
targeting IGF1R (insulin-like growth factor 1 
receptor), are the subjects of today's research for 
osteosarcoma treatment. 
Prognosis 
The multi-disciplinary approach of neoadjuvant 
chemotherapy, surgery and adjuvant chemotherapy 
has improved the survival of the patients from 10%-
20% up to 60%-70% in the past 20 years. Many 
potential markers (RB1, TP53 etc.) have been 
evaluated to predict patients prognosis, but till now 
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the histological response to chemotherapy is the 
most sensitive indicator of survival. This response is 
determined by histological examination of multiple 
sections from the resected tumor and grading the 
percentage of tumor necrosis. In those patients with 
a good response (defined as >90% tumour necrosis) 
long-term survival is generally 80-90%. However 
within the group of non-responders (necrosis <90%) 
the survival is usually 40-60%. 
Genetics 
Note 
Many other tumors of childhood e.g. Ewing sarcoma 
and hematological malignancies are mostly 
characterized by balanced chromosomal 
translocations or germline mutations. In contrast, 
conventional osteosarcoma shows extreme genetic 
instability, especially numerical aberrations and non-
recurrent inter- and intra-chromosomal 
rearrangements. About 50%is characterized by 
chromothripsis, a single cataclysmic event resulting 
in genomic rearrangements. The chromothripsis 
breakpoints often show clusters of point mutations, 
known as kataegis. Furthermore, around 80% of 
osteosarcomas show loss of heterozygosity and 
genomic instabilty signatures that are characterictic 
for BRCA-deficient tumours. 
Cytogenetics 
Note 
Conventional osteosarcomas are almost always 
hyperploid and show more amplifications than losses 
of genetic material. In the literature there is a general 
consensus about the gain of the chromosome arms 
8q, 17p and 6p while many other (sporadic) 
observations are also reported. The amplified region 
at 17p contains COPS3 gene which is suggested to 
be the target of this amplification because it is 
involved in the degradation of the p53 protein. The 
chromosomal region 6p12-21 contains the RUNX2 
gene, involved in terminal osteoblast differentiation. 
Furthermore, deletion or loss of heterozygosity at 
chromosome arm 3q13, where the LSAMP  gene is 
located, correlates with disease progression and poor 
survival. 
Genes involved and 
proteins 
Note 
TP53 and RB1, two well known tumor suppressor 
genes, are most commonly altered in osteosarcoma 
and will be discussed in more detail. Also other 
genes (table) as MDM2, CDKN2A (p16), MYC and 
CHEK2 have been reported to show alternations in 
osteosarcoma but are not completely studied yet. 
Recent next-generation sequencing (NGS) studies 
allowed for the identification of new genes involved 
in osteosarcoma. In particular genes involved in the 
IGFR-signaling pathway were discovered in 
different NGS-studies, where it was shown that 
around 14% of osteosarcomas show amplification of 
the IGF1 receptor.  Furthermore, around 24% of 
osteosarcomas contain genomic alterations in 
members of the PI3K/mTOR pathway. Other genes 
that were found in multiple NGS-studies are 
included in the table.  
 
Gene name  Location  Alteration  
COPS3  17p Amplification 
MYC  8q Amplification 
MYCN  1p Amplification 
FOS  14q Amplification 
CDK4  12q Amplification 
MDM2  12q Amplification 
TP53  17p Mutation  
RB1  13q Mutation  
RECQL4  18q Mutation  
CDKN2A  9p Mutation/deletion 
CHEK2  22q Mutation  
EZR  6q Amplification 
ATRX * Xq Mutation/deletion  
PTEN  10q Mutation  
* Although the ATRX gene is located on the X chromosome, 
there was no gender bias for mutations in this gene. 
TP53 (Tumour protein p53 (Li-
Fraumeni syndrome)) 
Location 17p13.1 
TP53 mutation (which is detected by increased 
levels of immunohistochemical staining because of 
the higher half life time caused by the mutation or 
sequencing) is detected in approximately 20% of 
high-grade central OSs. Recent next-generation 
sequencing studies that can detect structural 
variations conclude that the number of TP53 
alterations is much higher, namely around 90%. 
Most often there are translocations in the first intron 
of TP53, resulting in gene inactivation. As structural 
alterations cannot be detected by 
immunohistochemical staining, this can explain the 
lower number of TP53 alterations found by 
traditional methods.  
The mutation shows correlation with an increased 
genomic instability of the tumor but not with clinical 
outcome. Also amplification of the MDM2 gene 
(about 6%) and loss of the CHEK2 gene act on the 
same pathway by mediating TP53 degradation. 
Protein 
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TP53 plays an essential role in the regulation of cell 
cycle, specifically in the transition from G0 to G1. 
TP53 protein contains DNA-binding, 
oligomerization and transcription activation 
domains. It binds as a tetramer to a p53-binding site 
and activates expression of downstream genes that 
inhibit growth and/or invasion. Mutants of TP53 
mainly fail to bind the DNA binding site and loose 
the tumor suppressor activity. Alterations of the 
TP53 gene occur not only as somatic mutations in 
human malignancies, but also as germline mutations 




In accordance with TP53, in the RB1 pathway also 
other genes are reported to have alternations 
especially when RB1 is not affected. For example 
CDKN2A (p16) gene has been shown to be mutated 
in OSs that have no RB1 mutations. The group of 
patients that show CDKN2A (p16) loss without 
TP53 or RB1 alternations are thought to have even 
worse survival compared to the rest of the patients. 
Protein 
pRB (protein name of the RB1 gene) is usually 
present as a phosphoprotein inside cells and is a 
target for phosphorylation by several kinases. One 
highly studied function of RB1 is to prevent the cell 
from dividing or progressing through the cell cycle. 
The blockade in cell cycle progression is facilitated 
by p16 that inhibits CDK4/ CDK6 dependent 
phosphorylation. When pRB is ineffective at this 
role, mutated cells can continue to divide and may 
become tumorigenic. 
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